Peter Hammerl

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2021 · 516 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +9

Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome

Simone Rosseau, Peter Hammerl, Ulrich A. Maus et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2000 · 189 citations

Life Sciences, Cell Biology, Immunology +17

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

Donald E. Low, Thomas M. File, Paul B. Eckburg et al. · Journal of Antimicrobial Chemotherapy · 2011 · 185 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis

Toby M. Maher, Paul Ford, Kevin M. Brown et al. · JAMA · 2023 · 127 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 104 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16